Irene Martinez-Gonzalez
Valencia, VC 46010, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Enhanced muscle uptake of chemically optimized miR-23b antisense oligonucleotides as lead compounds for myotonic dystrophy type 1.
Journal: American journal of human genetics
Published: July 04, 2025
AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action.
Journal: Science advances
Published: October 09, 2024
Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression.
Journal: Molecular therapy. Nucleic acids
Published: July 12, 2022
Use of HSALR female mice as a model for the study of myotonic dystrophy type I.
Journal: Lab animal
Published: June 28, 2022
Rapid Determination of MBNL1 Protein Levels by Quantitative Dot Blot for the Evaluation of Antisense Oligonucleotides in Myotonic Dystrophy Myoblasts.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: February 25, 2022
Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model.
Journal: Molecular therapy. Nucleic acids
Published: September 15, 2021
Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy.
Journal: Molecular therapy. Nucleic acids
Published: October 18, 2020
Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy.
Journal: Molecular therapy. Nucleic acids
Published: April 16, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026